66335-38-4

Basic information

• Product Name: 5'-Deoxy-5-fluorocytidine
• Synonyms: 5'-DEOXY-5-FLUOROCYTIDINE;5-FLUORO-5'-DEOXYCYTIDINE;5'-DFCR;5'-Deoxy-5-fluoro-D-cytidine;5''-DEOXY-5-FLUOROCYTIDINE (5''-DFCR);5-Fluoro-5’-deoxycytidine, 5’-DFCR;Capecitabine Related Compound A (10 mg) (5'-deoxy-5-fluorocytidine);Deoxy-5-fluorocytidine-D2
• CAS NO: 66335-38-4
• Molecular Formula: C₉H₁₂FN₃O₄
• Molecular Weight: 245.21
• EINECS: 1806241-263-5
• Product Categories: Bases & Related Reagents;Nucleotides;Heterocycles
• Mol File: 66335-38-4.mol
• Article Data: 8

Chemical Properties

• Melting Point: 196-198°C
• Boiling Point: 437.874 °C at 760 mmHg
• Flash Point: 218.619 °C
• Appearance: White solid
• Density: 1.841 g/cm³
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 13.65±0.70(Predicted)
• Stability: HYGROSCOPIC
• CAS DataBase Reference: 5'-Deoxy-5-fluorocytidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5'-Deoxy-5-fluorocytidine(66335-38-4)
• EPA Substance Registry System: 5'-Deoxy-5-fluorocytidine(66335-38-4)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36-37/39-24/25
• Hazardous Substances Data: 66335-38-4(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Upstream product

• 154361-50-9 capecitabine 
• 66335-37-3 5'-deoxy-2',3'-O-isopropylidene-5-fluorocytidine 
• 933444-01-0 C₉H₁₁FN₂O₄S 
• 161599-46-8 (2R,3R,4R,5R)-2-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-5-methyl-tetrahydrofuran-3,4-diyl diacetate 
• 124012-42-6 5'-deoxy-5-fluoro-N⁴-(3,4,5-trimethoxybenzoyl)cytidine 

Downstream Products

• 154361-50-9 capecitabine 
• 161599-46-8 (2R,3R,4R,5R)-2-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-5-methyl-tetrahydrofuran-3,4-diyl diacetate 
• 124012-64-2 3'-O-benzoyl-5'-deoxy-5-fluorocytidine 
• 162204-35-5 N₄-(cyclohexyloxycarbonyl)-5'-deoxy-5-fluorocytidine 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII and formula VIII and, the methods for the treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases.

Design, synthesis and anti-tumoractivity of novel amidine derivatives of doxifluridine

A series of novel amidine derivatives of doxifluridine were synthesized using acid amide as the starting material, and their anti-tumor activity was evaluated in A549 cells. Compounds 10 and 11 demonstrated were more potent than 5-Fu, which was used as a positive control. Compound 10, which were found to be the most potent one with IC50 of 3.2 μmol/L, was 16 times more potent than 5-Fu with IC50 of 52 μM to the A549 cells. A new route was designed to synthesize 5′-deoxy-5-fluorocytidine. All compounds were characterized by 1H NMR, MS and X-ray spectras in detail.

MW-assisted Er(OTf)3-catalyzed mild cleavage of isopropylidene acetals in Tricky substrates

Erbium(III) trifluoromethane sulfonate is proposed as a very gentle Lewis acid catalyst in a MW-assisted chemoselective method for the cleavage of isopropylidene acetals in awkward substrates by using pure water as the solvent.